Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.
Beacon Therapeutics has raised $75.0M in total funding. The most recent round was Series C. The last funding was announced in January 2026.
Beacon Therapeutics's investors include TCG Crossover, Oxford Science Enterprises, Forbion Capital Partners, Goldman Sachs Alternatives, University of Oxford.
Beacon Therapeutics is headquartered in Alachua, United States.
Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.
Beacon Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Beacon Therapeutics — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/beacon-therapeutics. Accessed August 1, 2026.
VCBacked. (2026). Beacon Therapeutics — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/beacon-therapeutics
{{cite web |title=Beacon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/beacon-therapeutics |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated